---

---

sector : Health technology    tags : Disease   

save search

---

Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight
Published: 2024-04-24 (Crawled : 22:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| Email alert Add to watchlist
OTLK | News P | $8.2 0.0% 240K |

Health Technology

| Email alert Add to watchlist
KOD | News | $3.37 1.2% 1.19% 340K |

Health Technology

| Email alert Add to watchlist
OPT | News | $3.46 2.98% 2.89% 8.2K |

Health Technology

| Email alert Add to watchlist
disease market

---

Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
FRLN | $6.48 0.0% 0 |

Health Technology

| Email alert Add to watchlist
disease cell meeting parkinson’s therapy

---

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K |

Health Technology

| -2.06% | O: -0.17% H: 0.08% C: -1.9%
disease kidney treatment pharmaceuticals for study

---

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| 0.61% | O: 0.0% H: 0.0% C: 0.0%
entyvio fda disease active for therapy

---

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $14.0 8.11% 7.5% 2.3M |

Health Technology

| -8.2% | O: -15.02% H: 3.55% C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study

---

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K |

Health Technology

| 13.66% | O: 0.0% H: 7.32% C: -1.95%
disease neurology system meeting parkinson’s therapeutics

---

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K |

Health Technology

| -1.14% | O: -5.0% H: 4.19% C: 2.86%
disease vyvgart for

---

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 11:00) - prnewswire.com
EVGN | $0.7 -13.64% 63K |

Health Technology

| -0.87% | O: -0.87% H: 0.0% C: 0.0%
conference disease meeting week

---

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.02 -0.98% -0.99% 78K |

Health Technology

| -17.96% | O: 4.9% H: 6.03% C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical

---

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| -2.61% | O: 1.06% H: 0.47% C: -0.03%
fda device disease test granted blood designation for alzheimer's roche

---

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.505 1.01% 1.0% 1.9M |

Health Technology

| -14.29% | O: 0.57% H: 11.65% C: 4.55%
disease control treatment trial therapeutics

---

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M |

Health Technology

| -1.07% | O: 0.73% H: 2.49% C: 0.11%
abrysvo disease positive risk for rsv results study

---

New survey uncovers lack of awareness around heart valve disease and risk factors among women
Published: 2024-04-07 (Crawled : 12:20) - prnewswire.com
MDT | $80.38 -1.12% 0.0% 5M |

Health Technology

| Email alert Add to watchlist
disease risk women heart

---

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
AMRN | News | $0.8844 0.13% 0.12% 660K |

Health Technology

| Email alert Add to watchlist
disease cardiovascular show

---

Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
Published: 2024-04-05 (Crawled : 11:00) - prnewswire.com
LH 4 | $207.94 -0.01% 0.0% 790K |

Health Services

| -3.04% | O: -0.6% H: 0.0% C: 0.0%
OPK | $1.225 -2.0% -2.04% 6.1M |

Health Technology

| -10.22% | O: -0.73% H: 0.74% C: -0.74%
labcorp disease research molecular

---

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BWAY | $5.03 1.93% 1.89% 26K |

Health Technology

| -7.71% | O: 6.79% H: 0.0% C: -7.9%
disease parkinson's review treat potential results

---

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Published: 2024-04-01 (Crawled : 22:00) - globenewswire.com
OCGN | News 4 | $1.17 -6.4% -6.84% 7.3M |

Health Technology

| -26.25% | O: -10.0% H: 0.69% C: -4.17%
ocu410 disease review positive study

---

Diabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsight
Published: 2024-04-01 (Crawled : 22:00) - prnewswire.com
PKX | News | $71.38 -0.14% 0.0% 150K |

Non-Energy Minerals

| -6.17% | O: -0.77% H: 0.0% C: -0.85%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -6.11% | O: -0.77% H: 0.8% C: 0.74%
disease kidney growth market diabetic

---

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | $400.66 -1.05% -1.06% 810K |

Health Technology

| -4.13% | O: 0.56% H: 0.0% C: 0.0%
vx-147 disease kidney treatment trial

---

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
SLDB | $8.75 -3.95% -4.11% 140K |

Health Technology

| -40.76% | O: -9.02% H: 0.0% C: -7.65%
sgt-003 fda rare candidate disease designation duchenne therapy

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---